Reuters logo
2 months ago
BRIEF-Gilead receives approval in Canada for Vemlidy for treatment of chronic hepatitis b virus infection
June 19, 2017 / 10:11 AM / 2 months ago

BRIEF-Gilead receives approval in Canada for Vemlidy for treatment of chronic hepatitis b virus infection

June 19 (Reuters) - Gilead Sciences Inc

* Gilead receives approval in Canada for Vemlidy™ (tenofovir alafenamide) for the treatment of chronic hepatitis b virus infection

* Gilead Sciences Inc - Health Canada has granted a notice of compliance for vemlidy 25mg tablets

* Gilead Sciences - patients in vemlidy arm also experienced numerically higher rates of normalization of blood serum alanine aminotransferase (alt) levels

* Gilead Sciences Inc - study 108, study 110 met their primary endpoint of non-inferiority to viread Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below